Pharmaceutical Executive-01-01-2018

Pharmaceutical Executive

In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.

Pharmaceutical Executive
Features

January 12, 2018

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.

Columns
Pharmaceutical Executive

January 11, 2018

States will continue to press for price controls, while FDA will tackle opioids and promote innovation.

Pharmaceutical Executive
From the Editor

January 09, 2018

The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,

Pharmaceutical Executive

Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

Pharmaceutical Executive
Columns

January 08, 2018

Program puts a new-and very real-spin on patient nutrition.

Pharmaceutical Executive
Columns

January 01, 2018

Is getting more clarity on Brexit ramifications for pharma and European public health really at the top of new-year to-do lists?

Pharmaceutical Executive
Special Sponsored Section

January 01, 2018

Three pivotal developments that occurred in 2017 illustrate the growing relevance and influence of the Swiss pharmaceutical and life sciences industry on the world stage. Companies in Switzerland are also playing innovative roles in reshaping the pharma value chain and contemporary paradigm of healthcare provision.

Issue PDF
Pharmaceutical Executive

January 01, 2018

Click the title above to open the Pharmaceutical Executive January 2018 issue in an interactive PDF format.